CTOs on the Move

Advanced Cardiac Therapeutics Inc

www.actmed.net

 
Advanced Cardiac Therapeutics, Inc. is a pre-commercial, medical device company that designs and manufactures a catheter-based system for the treatment of patients with AFIB. AFIB is characterized by an irregular, often rapid heart rate that commonly causes poor systemic blood flow. The Company`s mission is to dramatically improve the treatment of AFIB through the introduction of products based on its proprietary catheter and generator system. ACT`s technology is the only system in the world to leverage feedback from four unique capabilities: temperature sensing, low irrigation flow rates, high resolution EGM attenuation and contact sensing. The ACT ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.actmed.net
  • 1278 Glenneyre Suite 139
    Laguna Beach, CA USA 92651
  • Phone: 949.500.0192

Executives

Name Title Contact Details

Funding

Advanced Cardiac Therapeutics Inc raised $45M on 05/02/2017

Similar Companies

MAWD Pathology

MAWD Pathology is a Kansas City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HealthCarts.com

HealthCarts.com is a Plymouth, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

KoKo

KoKo, LLC is a global respiratory information systems software developer and medical device manufacturing company. The exclusive provider of Iris™, the world`s first Integrated Respiratory Information System; and KoKo® pulmonary function testing, diagnostic spirometry, and respiratory home monitoring devices. Our expert, scalable software solutions and sophisticated data collection products empower healthcare providers to advance respiratory diagnostic processes and improve patient outcomes while meeting the demanding clinical and business objectives of thought leaders in respiratory care.

Gamma Medica-Ideas (GM-I)

Gamma Medica-Ideas (GM-I), Inc is a Northridge, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cyrano Therapeutics

The Cyrano team has developed a unique, proprietary intranasal product to restore function in patients with a chronic loss of taste and smell. This is a condition affecting at least 14 million people in the US and a similar number in Europe, having a significant impact on safety, quality of life and well-being.